|
시장보고서
상품코드
2131733
내분비 요법약(ETD) 시장 규모, 점유율 및 성장 분석 : 약제 클래스별, 투여 경로별, 적응증별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Endocrine Therapy Drugs (ETDs) Market Size, Share, and Growth Analysis, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 내분비 요법약(ETD) 시장 규모는 2024년에 217억 달러로 평가되며, 2025년 234억 8,000만 달러에서 2033년까지 441억 1,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 8.2%로 성장할 것으로 전망되고 있습니다.
전 세계 내분비 치료제(ETD) 시장은 종양학과의 융합을 통해 발전하고 있습니다. 이에 따라 분자 바이오마커에 기반한 약물 선택이 강화되고, 치료 선택지가 확대되고 있습니다. 유전체 프로파일링이 표준 관행으로 자리 잡음에 따라 임상의들은 특정 에스트로겐 수용체 변이를 가진 환자에게 아로마타제 억제제나 CDK4/6 억제제를 효과적으로 처방할 수 있게 되었으며, 이는 반응률 향상과 가격 책정의 정당화로 이어지고 있습니다. 이러한 환경은 동반 진단에 대한 투자를 촉진하는 동시에, 분석법 개발에 초점을 맞춘 제약사와 생명공학 기업 간의 제휴도 지원하고 있습니다. 또한 인공지능(AI)은 표적 검증을 가속화하고, 분자 설계를 최적화하며, 유전체 프로파일을 평가하여 치료를 개인화함으로써 ETD 분야의 신약 개발 및 환자 선별에 혁신을 가져오고 있습니다. 그 결과, 협력 강화와 환자 치료에 대한 혁신적인 접근 방식을 특징으로 하는 역동적인 시장이 형성되고 있습니다.
전 세계 내분비 치료제(ETD) 시장 촉진요인
유방암, 전립선암, 난소암 등 호르몬 의존성 암의 유병률 증가가 효과적인 내분비 치료제에 대한 수요를 크게 부추기고 있습니다. 환자 수가 계속 증가함에 따라 의료 종사자들은 질병의 진행을 관리하고 환자의 삶의 질(QOL)을 향상시키기 위해 이러한 치료법에 점점 더 주목하고 있습니다. 이러한 추세에 따라 제약 기업은 새로운 치료법 개발 및 판매 채널 확대에 투자하게 되었으며, 이는 시장의 추가적인 성장을 촉진하고 있습니다. 또한 일반 대중의 인식 제고와 정기 검진의 보급으로 암 조기 발견이 촉진되어, 최적의 임상 결과를 얻기 위해 내분비 요법을 적시에 시행할 수 있게 되었습니다.
전 세계 내분비 요법제(ETD) 시장의 제약 요인
새로 승인된 내분비 요법제의 높은 가격은, 특히 보험 환급 정책이 제한적인 지역에서 환자와 의료 시스템 모두에게 큰 장벽이 되고 있습니다. 이러한 높은 비용은 종종 약제 접근의 지연이나 제한으로 이어지며, 의료 제공자들은 가능한 한 저렴한 치료 옵션을 모색할 수밖에 없게 됩니다. 이러한 경제적 부담은 치료법의 보편적인 보급을 방해할 뿐만 아니라, 처방약 리스트 등재를 제한하고, 궁극적으로 지불 주체가 엄격한 가격 협상을 진행함으로써 시장 성장을 저해하게 됩니다. 또한 예산 제약에 직면한 병원에서는 고가의 전문 의약품보다 필수 의료 서비스를 우선시하는 경우가 많아, 이러한 치료법에 대한 수요를 더욱 감소시키고 있습니다.
전 세계 내분비 치료제(ETD) 시장 동향
전 세계 내분비 치료제(ETD) 시장은 표적 면역제와 호르몬 요법을 결합한 정밀 면역 요법의 통합으로 인해 큰 변화를 겪고 있습니다. 이 혁신적인 접근 방식을 통해 임상의는 유방암이나 전립선암에서 널리 관찰되는 내성 기전에 대처할 수 있게 되었습니다. 제약사들은 치료 효과와 반응 지속 기간을 높이는 병용 요법을 개발하기 위해 공동 연구에 적극적으로 나서고 있습니다. 이러한 전략은 학제 간 임상시험 설계를 촉진하고 규제 당국과의 협력을 강화할 뿐만 아니라, 치료가 어려운 질환 표현형을 가진 환자를 위한 치료 선택지의 다양화에도 기여하고 있습니다. 그 결과, 정밀 면역요법은 전 세계 암 치료 패러다임의 진화에서 매우 중요한 요소로 자리 잡고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 내분비 요법약(ETD) 시장 규모 : 약제 클래스별
세계의 내분비 요법약(ETD) 시장 규모 : 투여 경로별
세계의 내분비 요법약(ETD) 시장 규모 : 적응증별
세계의 내분비 요법약(ETD) 시장 규모 : 유통 채널별
세계의 내분비 요법약(ETD) 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSAGlobal Endocrine Therapy Drugs (Etds) Market size was valued at USD 21.7 Billion in 2024 and is poised to grow from USD 23.48 Billion in 2025 to USD 44.11 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).
The global Endocrine Therapy Drugs (ETDs) market is advancing due to the integration of oncology, which enhances drug selection based on molecular biomarkers and broadens therapeutic options. As genomic profiling becomes standard practice, clinicians can effectively prescribe aromatase inhibitors and CDK4/6 blockers to patients with specific estrogen-receptor mutations, boosting response rates and supporting their pricing. This environment fosters investment in companion diagnostics, along with collaborations between pharmaceutical and biotech firms focused on assay development. Additionally, artificial intelligence is transforming drug discovery and patient selection within the ETDs sector by accelerating target validation, optimizing molecule design, and assessing genomic profiles to tailor treatments. The result is a dynamic market characterized by increased collaboration and innovative approaches to patient care.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Endocrine Therapy Drugs (Etds) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Endocrine Therapy Drugs (Etds) Market Segments Analysis
Global endocrine therapy drugs (etds) market is segmented by drug class, route of administration, indication, distribution channel and region. Based on drug class, the market is segmented into Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors (AIs), Selective Estrogen Receptor Degraders (SERDs), GnRH Agonists & Antagonists and Androgen Receptor Inhibitors. Based on route of administration, the market is segmented into Oral and Injectable. Based on indication, the market is segmented into Breast Cancer, Prostate Cancer, Endometrial Cancer and Other Hormone-Dependent Cancers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Endocrine Therapy Drugs (Etds) Market
The increasing prevalence of hormone-driven cancers, such as breast, prostate, and ovarian cancers, is significantly fueling demand for effective endocrine therapy drugs. As the patient population continues to grow, healthcare professionals are increasingly turning to these treatments to manage disease progression and enhance patient quality of life. This trend is encouraging pharmaceutical companies to invest in the development of new therapies and broaden their distribution channels, further stimulating market expansion. Additionally, a rise in public awareness and regular screening practices facilitates earlier cancer detection, enabling the timely use of endocrine therapies for optimal clinical outcomes.
Restraints in the Global Endocrine Therapy Drugs (Etds) Market
The high price tag associated with newly approved endocrine therapy drugs acts as a considerable obstacle for both patients and healthcare systems, especially in areas where reimbursement policies are limited. These elevated costs frequently result in delayed or restricted access to medications, causing healthcare providers to explore more affordable treatment options whenever possible. This financial burden not only hinders universal acceptance but also restricts drug inclusion in formularies, ultimately impeding market growth as payers enforce strict pricing negotiations. Moreover, hospitals facing budget limitations often favor essential services over high-cost specialty drugs, further diminishing demand for these therapies.
Market Trends of the Global Endocrine Therapy Drugs (Etds) Market
The Global Endocrine Therapy Drugs (ETDs) market is experiencing a significant shift due to the integration of precision immunotherapy, which combines targeted immune agents with hormonal therapies. This innovative approach facilitates clinicians in tackling resistance mechanisms prevalent in breast and prostate cancers. Pharmaceutical companies are actively engaging in collaborative research to develop combination regimens that enhance treatment efficacy and response longevity. This strategy not only promotes interdisciplinary trial designs and fosters regulatory interactions but also diversifies therapeutic options for patients with challenging disease phenotypes. As a result, precision immunotherapy is becoming a pivotal element in the evolution of global cancer treatment paradigms.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Endocrine Therapy Drugs (ETDs) Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors (AIs)
- Selective Estrogen Receptor Degraders (SERDs)
- GnRH Agonists & Antagonists
- Androgen Receptor Inhibitors
Global Endocrine Therapy Drugs (ETDs) Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Injectable
Global Endocrine Therapy Drugs (ETDs) Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Breast Cancer
- Prostate Cancer
- Endometrial Cancer
- Other Hormone-Dependent Cancers
Global Endocrine Therapy Drugs (ETDs) Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Endocrine Therapy Drugs (ETDs) Market Size & CAGR (2026-2033)
- North America (Drug Class, Route of Administration, Indication, Distribution Channel)
- US
- Canada
- Europe (Drug Class, Route of Administration, Indication, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Route of Administration, Indication, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Route of Administration, Indication, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Route of Administration, Indication, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GSK plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exelixis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Accord Healthcare Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
